Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel? Vrije Universiteit Brussel University of Antwerp
Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. Immune checkpoint inhibitors (ICIs) have drawn a lot of attention last years because of their promising response rates and their durable effects. ICIs are currently widely used in the ...